Stage NPDR using any one 4-2-1 criterion without new vessels. PDR treatment extends beyond high-risk disease. Anti-VEGF is first line for most visually impaired centre-involved DMO, while selected good-vision eyes may be monitored with a rescue plan. In NVG, injections buy time while pressure and ischaemia are addressed. Aspirin evidence is not a reason to change prescribed antithrombotic treatment yourself.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Assess the retina and the systemic risks together
Diabetic retinopathy (DR) is a leading cause of preventable blindness in working age and a marker of systemic microangiopathy. Retina, kidney and nerve share the same small-vessel injury, so the eye finding is also a message about the heart, the kidney and blood pressure. Three concepts organise the lecture: follow non-proliferative DR (NPDR) according to stage; control neovascularisation in proliferative DR (PDR); and treat diabetic macular oedema (DMO), an important cause of visual loss, to preserve function as well as improve anatomy. 1 2
Treatment goals are therefore threefold: preserve vision by controlling oedema and preventing macular haemorrhage; make new vessels regress so that vitreous haemorrhage and traction are avoided; and keep the systemic base stable with the diabetes team. The original claim that any injection or laser is “doomed to fail” if HbA1c and blood pressure are neglected is too strong: ocular treatment still helps, and systemic control lowers risk alongside it. HbA1c describes roughly the last three months. The “legacy effect” means that years of poor control leave a risk that a short period of improvement before surgery does not immediately erase. That is an argument for long-term control and for not delaying urgently needed eye treatment while waiting for a perfect HbA1c. 1 2
Aspirin and anticoagulants: in the ETDRS, 3711 patients with mild-to-severe NPDR or early PDR were randomised to aspirin 650 mg daily or placebo; aspirin neither prevented high-risk PDR nor increased vitreous haemorrhage. This is randomised evidence about aspirin, not a safety guarantee for every anticoagulant, and it is not a reason to stop or start any such drug yourself. 7
Screening schedules depend on age and diabetes type. ADA 2026 recommends the first comprehensive dilated examination within 5 years of adult type 1 diagnosis and at type 2 diagnosis. For youth with type 1 diabetes, start after 3–5 years of disease once age ≥11 or puberty has begun, whichever comes earlier. Pre-existing diabetes needs assessment before pregnancy and in the first trimester, with follow-up during pregnancy and up to 1 year postpartum according to disease; gestational diabetes alone is a different situation. Symptoms require assessment regardless of the screening date. 13 14
The original prevalence figures are DR about 35% and DMO 6.8%, with DR in 15% after 5 years, over 80% after 20 and almost 90% after 30 years. Cohort, diabetes type, era and definitions are untraced, so these are historical teaching estimates, not current universal risks or proof that DR is the most frequent diabetic complication. 1
Duration, glycaemia, age at diagnosis, nephropathy, hypertension, smoking and obesity inform risk. The source’s HbA1c about 7% is an example, not a target suitable for every patient. Its annual mild-NPDR, 6–12-month moderate and 4-month severe/non-high-risk-PDR schedules, with 2–3-month high-risk follow-up, are historical examples; active high-risk disease needs treatment rather than waiting for a calendar visit. 1
02Ischaemia, VEGF and what treatment can and cannot change
The chain is short and worth memorising: capillary occlusion causes tissue hypoxia; the hypoxic retina secretes vascular endothelial growth factor (VEGF); VEGF increases vessel permeability and drives new vessel growth. Pericyte loss is an early histological event in diabetic microangiopathy and destabilises the blood–retinal barrier. The original description of this as an irreversible “point of no return” is too absolute: pericyte loss precedes capillary occlusion, and barrier function and oedema can improve with treatment. 1 2
Anti-VEGF suppresses the permeability and growth signal while treatment is effective; panretinal photocoagulation (PRP) reduces the peripheral retinal drive. Anti-VEGF can be an alternative to PRP in selected PDR with reliable repeated treatment and follow-up, or an adjunct. PRP is more durable but does not eliminate recurrence or the need for review. In NVG, rapid regression after injection still needs treatment of the ischaemic cause and pressure. 2 5 12 13
Endothelial-cell injury and basement-membrane thickening accompany pericyte loss. Leakage and capillary closure overlap in DR, which affects the macula as well as the periphery; DMO is a complication within diabetic retinal disease, not an entirely separate disease. The two original patient examples remain useful: advanced peripheral new vessels can coexist with good central vision, while major macular oedema can impair vision with relatively mild peripheral signs. 1
03Classification: the 4-2-1 rule and the border to PDR
Grading follows the ETDRS photographic severity scale, which has 13 levels and was built from the power of haemorrhages, microaneurysms, IRMA and venous beading to predict progression. Clinical practice uses the simplified five-stage international scale: no retinopathy, mild, moderate and severe NPDR, and PDR. 3 4
Severe NPDR requires any one of the 4-2-1 criteria, without PDR signs: more than 20 intraretinal haemorrhages in each of 4 quadrants, definite venous beading in at least 2 quadrants, or prominent intraretinal microvascular abnormalities (IRMA) in at least 1 quadrant. They are alternatives, not a requirement to meet all three. Any neovascularisation of the disc (NVD) or elsewhere (NVE) makes the eye PDR. 3 4 15
The lecture's figure of “up to 50% conversion to PDR within one year” is a historical teaching figure for severe NPDR. It is useful for explaining why review intervals shorten, but it is not a universal rate for every stage, population or level of control, and this draft did not re-verify the exact percentage in the sources read. 1 3
IRMA are intraretinal irregular vascular loops; NVE extends through the internal limiting membrane (ILM) onto the retinal surface or into the vitreous. IRMA usually leak little on fluorescein angiography, but leakage and evolution towards neovascularisation can occur. Combine the vascular appearance, leakage and OCT location rather than treating any single sign as infallible. 1 3 9
Mild NPDR has microaneurysms only; moderate lies between mild and severe. “Very severe” historically means at least two 4-2-1 criteria without PDR. Examine acuity, slit lamp including iris, pressure and dilated retina, using FA for specific leakage/perfusion questions rather than making it compulsory for every diagnosis. NVI/NVA signals urgent anterior neovascular risk; vitreous blood must be interpreted with its cause rather than automatically called PDR. 1
04PDR: which eye is high-risk and when to laser
PDR means any neovascularisation, at the disc or elsewhere. Not every PDR is high-risk, and this difference decides urgency. The Diabetic Retinopathy Study identified four risk factors, and eyes with three or more — the “high-risk characteristics” — had a much higher two-year risk of severe visual loss. The classical high-risk features are NVD of about one-quarter to one-third disc area, any NVD with vitreous or preretinal haemorrhage, and NVE of at least half disc area with haemorrhage. The “one-quarter to one-third” range comes from that historical DRS context; it is a treatment threshold, not a description of all PDR, and a smaller NVD with haemorrhage is still high-risk. 6
ETDRS report 9 compared early scatter photocoagulation with deferral. Scatter was not recommended for mild or moderate NPDR, should be considered when retinopathy is more severe, and usually should not be delayed once high-risk PDR is present. The same report documented short-term adverse effects on visual acuity and visual field, greatest immediately after treatment and smaller with less extensive scatter. 5
PRP is offered for PDR beyond the high-risk subgroup; NICE recommends offering it at first diagnosis, with greater urgency for high-risk features or unreliable attendance. Anti-VEGF can be an alternative in selected PDR or an adjunct, but requires reliable follow-up, repeated dosing and attention to traction. The historical high-risk thresholds guide urgency, not a rule to withhold treatment from all other PDR. 5 12 13
PRP parameters in the table are original examples, not a universal laser prescription; lens magnification, pulse system, retinal response and adverse effects matter. Neovascular regression does not restore capillary perfusion. The export’s claim of ranibizumab-only PDR approval and its added aflibercept approval claim require current jurisdiction- and product-specific labels; neither is confirmed by efficacy evidence alone. 1
Original PRP spacing of 1–1.5 spot diameters and approximately 2000 burns across sessions are examples, not a fixed German standard. Lens magnification (original Goldmann ×2), pulse system, scar expansion and retinal response matter. Recurrent activity may require further sessions over months or years; this does not justify delaying urgent initial treatment. 1
Concurrent centre-involving DMO and PDR may favour combined planning: injections can treat oedema and suppress new vessels, but do not automatically eliminate PRP or follow-up. Each injection carries endophthalmitis risk. Comparative field preservation, repeated visits, costs and reliable access belong in shared decisions; neither repeated FA at every visit nor universal pragmatic superiority of laser follows. The original 2019 exclusive-Lucentis licensing claim and up-to-70% German Avastin share remain unverified local/dated claims, not prescribing authority. 1
05Diabetic macular oedema: treat the centre and the function, not a fixed number
DMO is an important cause of visual loss in diabetes. Centre involvement matters for reading vision; OCT describes retinal thickness, intraretinal and subretinal fluid and hyperreflective foci. Anatomy informs the decision but is not a substitute for visual function. The original rule “centre involvement plus vision below 0.7 (about 20/30)” describes a common situation, not a legal threshold. The decision combines centre involvement, duration, functional symptoms and the fellow eye; a patient with 1.0 vision and new metamorphopsia may be treated, but the symptom alone does not automatically require an injection. 2 8 9
Protocol V randomised 702 eyes with centre-involved DMO and vision 20/25 or better to initial aflibercept, laser or observation. At 2 years, loss of at least 5 letters occurred in 16%, 17% and 19%, respectively, without a statistically clear difference; this does not prove equivalence. Rescue aflibercept was needed in 25% of laser and 34% of observation eyes. These selected good-vision eyes had structured follow-up and rescue criteria; the findings do not justify unmonitored waiting or apply to every visually impaired eye. 8
Anti-VEGF is first line for most centre-involved DMO with visual impairment, not automatically every good-vision eye. Options include aflibercept, ranibizumab and the dual VEGF-A/Ang-2 inhibitor faricimab. YOSEMITE/RHINE included 1891 participants: protocol-defined schedules, fixed 8-week treatment or personalised faricimab intervals of 4–16 weeks supported non-inferiority at 1 year against 8-week aflibercept within a 4-letter ETDRS margin. This industry-funded trial does not establish superiority or validate every real-world treat-and-extend schedule. 11 13
Consider intravitreal steroids in selected persistent DMO or when anti-VEGF is unsuitable; pseudophakia alone is not an automatic indication. Dexamethasone implant (Ozurdex) and triamcinolone differ in formulation and local authorisation. Assess pressure rise, cataract, contraindications and the exact product monitoring requirements; no blanket licence or safety equivalence is implied. 10
Focal or grid laser keeps specific indications: non-centre oedema, localised leaking microaneurysms, and eyes where injections are not feasible. It is no longer first line for centre-involved oedema. OCT angiography adds information about the foveal avascular zone (FAZ). An enlarged FAZ suggests macular ischaemia and predicts a poorer response, but it is not a fixed ceiling on vision, and OCT-A is prone to projection, segmentation and signal artefacts. Treat the patient, not the FAZ measurement alone. 2 9
Describe focal/diffuse leakage separately from macular perfusion and centre involvement. FA shows leakage, OCT thickness and cysts/SRF, and OCT-A flow with artefact limits; no single image measures every function. Ischaemia and ellipsoid-zone disruption can limit prognosis but do not establish no treatment benefit or a fixed visual ceiling. 1
The original agent list retains ranibizumab/Lucentis, aflibercept 2 mg/8 mg/Eylea, brolucizumab/Beovu, faricimab/Vabysmo and off-label bevacizumab/Avastin. Aflibercept also binds PlGF, while faricimab targets VEGF-A and Ang-2. Check the exact local indication, safety and dosing; brolucizumab requires particular inflammation/retinal-vasculitis attention. Insurance and biosimilar availability affect access but do not establish clinical superiority. 1
The original 3–6 monthly loading injections are not interchangeable across drugs or labels. In treat-and-extend, planned treatment and monitoring guide a personalised interval; complete dryness is not the sole universal extension criterion. PRN requires planned review and retreatment criteria, not simply waiting for symptoms. The original cultural preference for PRN is a discussion point, not a population-wide adherence rule; early 8 mg experience cannot prove superior vision over 2 mg. 1
Retain triamcinolone off-label, dexamethasone/Ozurdex and fluocinolone/Iluvien as distinct options. Cataract and pressure rise are important but neither inevitable in every phakic eye nor identical across products; glaucoma contraindications depend on the exact label and status. Focal/grid or navigated/pattern laser is not inherently risk-free. Vitreomacular traction can make PPV relevant, but a VMT label alone does not mandate surgery; balance functional impairment, anatomy and risks. 1
06Read OCT biomarkers as context, not an automatic switch rule
Large cysts (original >380 µm), subretinal fluid, hyperreflective dots, disorganisation of retinal inner layers (DRIL), ellipsoid-zone (EZ) damage and vitreomacular traction (VMT) describe different processes. Prognostic association does not validate a treatment-predictive cutoff: fluid/dots alone do not prove steroid-responsive inflammation, and DRIL alone does not prove irreversible ischaemia. Review segmentation, chronicity, acuity and treatment exposure before switching. 1
RetinAI Fluid Monitor is the original named AI example for quantifying fluid. Quantification needs image-quality checks, valid segmentation and human interpretation; the name alone establishes neither current local authorisation nor better patient outcomes. PASCAL, Navilas and subthreshold micropulse remain distinct laser approaches, not uniformly safer replacements. PPV with membrane/ILM peeling may help selected tractional cases; prophylactic surgery without VMT remains uncertain and requires a separate benefit–risk assessment. 1
07A longitudinal case: anatomy improves, visual recovery remains limited
The original case describes a 57-year-old woman with type 1 diabetes for 25 years and HbA1c 10.4%. Severe bilateral DMO and peripheral ischaemia were present without initial PDR. Avastin and initial peripheral laser were followed by improved acuity and oedema. This is an educational case narrative, not independently verified patient records or a controlled comparison. 1
After a 1-year follow-up gap, severe recurrent DMO, visual decline and new proliferative vessels were recorded, with right-eye VMT. The account reports 11 right-eye and 13 left-eye injections and completion of PRP, followed by right PPV for persistent oedema with traction. The gap identifies a need to address access and continuity; the narrative cannot attribute all progression to patient behaviour. 1
Right oedema reportedly resolved completely and acuity improved from hand movements to decimal 0.1, with no further injections recorded in the described interval. Anatomical resolution and partial functional recovery differ. Follow-up duration and independent verification are missing: this case cannot establish permanent injection freedom, universal PPV efficacy or prophylactic benefit without traction. 1
| PRP parameter | Original example | Clinical boundary |
|---|---|---|
| Spot diameter | 300–500 µm | Account for lens magnification, e.g. Goldmann ×2; no universal preset |
| Exposure | 0.15–0.2 s | Original mild/moderate whitening; titrate to system and tissue |
| Number | About 2000 | Several sessions if appropriate; urgency and activity determine completion |
| Group | Original interval, with individualisation |
|---|---|
| Type 1 | Annual from 5 years; adult/youth initial-screening rules differ |
| Type 2 | Annual from diagnosis; adjust to findings |
| Mild NPDR | Annual example; symptoms assessed earlier |
| Moderate NPDR | 6–12 months example, not fixed for all |
| Severe NPDR | Original 4 months; shorten for progression/treatment planning |
| Non-high-risk PDR | Original 4 months is not permission to defer active PDR treatment |
| OCT biomarker | Interpretation | Treatment boundary |
|---|---|---|
| Large cysts >380 µm | Original adverse-response association | Cutoff unvalidated here; no inevitable failure |
| SRF / hyperreflective dots | Possible disease-context information | Not proof of inflammation or automatic early steroid switch |
| DRIL | Inner-layer disorganisation, possible adverse prognosis | Not a stand-alone proof of ischaemia/neurodegeneration |
| EZ integrity | Outer-retinal functional context | Damage may limit recovery, no fixed visual ceiling |
| VMT | Mechanical traction may maintain oedema | Consider selected PPV, not automatic surgery |
| Entity | Findings | Decision | Options and limits |
|---|---|---|---|
| Mild/moderate NPDR | Microaneurysms, haemorrhages; may be asymptomatic | Stage-based surveillance, assess macula separately | Systemic control; not automatic PRP |
| Severe NPDR | 4-2-1, progression risk | Consider early PRP in selected circumstances | No universal mandatory PRP; plan reliable follow-up |
| PDR | NVD/NVE, possible vitreous blood | Treat, more urgently if high risk | PRP; selected anti-VEGF with repeat treatment and follow-up |
| Non-centre DMO | Oedema/exudates, acuity may be good | Assess leakage, progression and function | Selected focal laser or surveillance, not mandatory laser for all |
| Centre DMO | Central oedema with variable acuity | Visual impairment usually favours treatment; selected good-vision eyes may be monitored | Anti-VEGF; selected steroids with safety assessment |
| DMO with VMT | OCT traction and oedema | Assess symptoms, persistence and alternatives | Selected PPV/membrane peeling; injection resistance alone is insufficient |
What are the main learning points?
Stage NPDR using any one 4-2-1 criterion without new vessels. PDR treatment extends beyond high-risk disease. Anti-VEGF is first line for most visually impaired centre-involved DMO, while selected good-vision eyes may be monitored with a rescue plan. In NVG, injections buy time while pressure and ischaemia are addressed. Aspirin evidence is not a reason to change prescribed antithrombotic treatment yourself.
When is assessment urgent?
Sudden visual loss, a painful red eye, pressure rise or rubeosis, dense vitreous haemorrhage, suspected detachment, marked inflammation or infection, and neurological warning signs require urgent assessment. Do not attribute an acute problem to diabetes without excluding other causes.
References and access status
- 1Immutable original export; own DR/DMO lecture and longitudinal case; recording unchecked
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2German S3 guideline on retinal complications of diabetes 2025 (AWMF 045-024)
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Historical selected access reused from earlier review ledgers and editorially compared; no fresh complete retrieval or full-source appraisal claimed. Exact prior scope is recorded in evidence.md.
- 3Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98 (5 Suppl):823-833. PMID 2062515
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 4Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677-1682. PMID 13129861
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 5Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98 (5 Suppl):766-785. PMID 2062512
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 6Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. Arch Ophthalmol 1979;97:654-655. PMID 426679
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 7Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991;98 (5 Suppl):757-765. PMID 2062511
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 8Protocol V randomised trial: Baker CW, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity. JAMA 2019. PMID 31037289
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 9OCT biomarkers systematic review 2025 (diabetic macular oedema). PMID 40803536
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Historical selected access reused from earlier review ledgers and editorially compared; no fresh complete retrieval or full-source appraisal claimed. Exact prior scope is recorded in evidence.md.
- 10EMA Ozurdex EU product information (dexamethasone intravitreal implant)
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Historical selected access reused from earlier review ledgers and editorially compared; no fresh complete retrieval or full-source appraisal claimed. Exact prior scope is recorded in evidence.md.
- 11YOSEMITE/RHINE faricimab phase 3 one-year report. PMID 35085503
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.
- 12NICE NG242: diabetic retinopathy recommendations (2024)
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Selected indexed NICE NG242 recommendations 1.5.1–1.5.5 independently read 15 November 2026; direct page access returned 403. Earlier DMO access is historical reuse; not a complete guideline appraisal.
- 13ADA Standards of Care 2026, section 12: retinopathy
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Selected official indexed recommendation/definition read 15 November 2026; not the entire document or evidence reviews.
- 14ADA Standards of Care 2026, section 14: youth screening
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Selected official indexed recommendation/definition read 15 November 2026; not the entire document or evidence reviews.
- 15AAO Diabetic Retinopathy Preferred Practice Pattern 2025: international severe NPDR definition
Historical 168-dr-dmo-guide appraisal reused; not new full-source access. Historical Review 123 recorded access reused; Selected official indexed recommendation/definition read 15 November 2026; not the entire document or evidence reviews.
Original lecture link
For patients
This chapter explains how diabetes damages the retina: the stages, the fluid at the macula, the bleedings and the pressure rise that can follow. It separates what treatment can change from what it cannot.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, a painful red eye, pressure rise or rubeosis, dense vitreous haemorrhage, suspected detachment, marked inflammation or infection, and neurological warning signs require urgent assessment. Do not attribute an acute problem to diabetes without excluding other causes.
Sudden visual loss, a painful red eye, pressure rise or rubeosis, dense vitreous haemorrhage, suspected detachment, marked inflammation or infection, and neurological warning signs require urgent assessment. Do not attribute an acute problem to diabetes without excluding other causes.